Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
Stem Cell Patents Webinar and BIO Int’l Convention Symposium
Patent Claims Coverage Webinar: Stem Cell Industry – Osiris Therapeutics – Amgen’s EPO – Wed., April 28, 12:00PM – 12:50PM CDT Sunlight Research™ invites you to attend a Stem Cell Industry Patent Claims Coverage webinar presented by Robin A. Chadwick, … Continue reading
The Return Of The Magnificent Prosecution Specialists Or Just More “QA”?
The USPTO recently announced the creation of an ombudsman program to resolve applicant/examiner logjams in all of the Tech Centers. This is a move that the Office (and practitioners) have needed badly for a number of years, ever since the … Continue reading
Posted in USPTO Practice and Policy
Tagged biotechnology law, intellectual property, ip, Patent Law, USPTO, Warren Woessner
Leave a comment
FYI
LES Spring Meeting — Boston, MA – May 19-21, 2010 I will be part of a Workshop entitled “A Shot Across the Bow – The Process Behind the Making and Responding to Demands to License Patented Technology” scheduled for May … Continue reading
Posted in About SLW, Conferences and Classes
Tagged About SLW, intellectual property, ip, LES, Schwegman Lundberg Woessner, Warren Woessner
Leave a comment
Is The “Golden Rule” Of Biological Drugs At Hand?
I just finished speaking on IP issues involving biomarkers at a Q1 Conference in the Bay Area. Before the conference started, I spoke to the head patent counsel of a well-known bio/pharma company. He said, to my initial shock, that … Continue reading